Ozempic vs Mounjaro: Semaglutide vs Tirzepatide

Why this comparison matters

Tirzepatide is a dual GIP and GLP-1 receptor agonist; semaglutide is GLP-1 only. The SURMOUNT and SURPASS trials show tirzepatide tends to drive more weight loss, but tolerability differs. This comparison breaks down the practical decision factors that matter to most patients — price, drug type, included services, and operational structure.

Which should you pick?

This is a closer call. Tirzepatide is a dual GIP and GLP-1 receptor agonist; semaglutide is GLP-1 only. The SURMOUNT and SURPASS trials show tirzepatide tends to drive more weight loss, but tolerability differs. Read both full reviews and decide based on your specific priorities:

FAQ

Can I switch between and ?

Yes. Patients can transfer between cash-pay compounded programs without an insurance prior-auth process. Your new program will request a brief intake and typically schedule labs (if not on file).

Is one safer than the other?

Both providers in this comparison meet baseline safety verification. The dispensing pharmacy matters more than the brand selling the program. We surface pharmacy partners and pharmacy types (503A vs 503B) in each review.

Which has better long-term outcomes data?

Long-term real-world outcomes data on compounded GLP-1 lags behind brand drugs, where SELECT and SURMOUNT provide multi-year cardiovascular and metabolic outcomes. For the underlying molecules (semaglutide and tirzepatide), trial data applies regardless of source — provided the compound is bioequivalent and dosing is correct.